PRODUCTS AND SERVICES
The company focuses on three main business sectors: generic APIs, advanced intermediates and CDMO. The products cover therapeutic areas such as oncology, anti-infection, hepatobiliary system, gastrointestinal system, nervous system, etc.
ABOUT US
Company Profile
Sichuan Taienkang Pharmaceutical Co., Ltd. is a holding subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. (stock code: 301263). It is a pharmaceutical company that integrates the research and development, production, and sales of generic APIs (active pharmaceutical ingredients) and advanced intermediates. The company was established in 2020, with a factory located in Yuechi County, Sichuan Province, China. The site covering a total area of 66,745 square meters. The production workshops are strictly in compliance with cGMP standards and the production capacity is expected to reach 300 MT/year. The product portfolio covers a wide range of therapeutic areas and is designed and developed with technical barriers to bring value-added products.
Time of Establishment
Total Area(㎡)
Capacity (MT/year)
Three R&D bases with strong and experienced teams. Process optimization and production cost reduction.
The factory plans to build 6 production workshops with 500L-5000L multifunctional reactors that comply with GMP standards and can meet clients’ needs for pilot/validation/commercial production.
The company has a professional quality management team and state-of-the-art equipment and instruments, providing clients with quality study and stability study services for APIs and intermediates to ensure they meet application requirements. These include analytical method development/optimization, analytical method validation/transfer, specification research, stability studies, product release testing etc.
The company has a professional, efficient, and experienced regulatory affairs team that can provides clients with CMC/DMF documents for domestic and international drug registration.
Video Center
R&D Center-Shandong Hubble Kisen
NEWS
Taienkang will participate in CPHI – JAPAN 2024
Sichuan Taienkang Pharmaceutical Co., Ltd. will be participating as an exhibitor in the CPHI – JAPAN 2024 at Tokyo Big Sight, Tokyo, Japan.
22
2024-03
CKBA, an innovative drug of Taienkang, launched the Phase II clinical trials.
On Nov. 17th, 2023, the press conference on the Phase II Clinical Trial Protocol of Innovative Drug and the China Diagnosis and Treatment Consensus Seminar for the Treatment of Vitiligo Disease were held in Shanghai. At the meeting, Taienkang officiallly announced the launch of its CKBA vitiligo drug phase II clinical trial. The day before this day, a Taienkang's subsidiary company, BCY pharm, just completed the first examinee (the patient) enrollment for the Phase II clinical trial for the Class I innovative drug-CKBA (Saccinic Acid) ointment for the treatment of vitiligo.
21
2023-11
Sichuan Taienkang Pharmaceutical Co., Ltd attended the CPHI Worldwide 2023.
CPHI Worldwide 2023 was hold in Barcelona from Oct.24th to 26th . CPHI has held over 30 sessions and is the world's largest pharmaceutical industry professional exhibition, covering the entire supply chain of the pharmaceutical industry. Sichuan Taienkang Pharmaceutical Co., Ltd. attended this grand event as an exhibitor for the first time and advertised the products for APIs & intermediates, bio-generic drugs and FDFs. During the three-day exhibition, the company's products attracted many customers from all over the world, and the booth was bustling with visitors! In the future, Taienkang will take participating in such exhibitions as an opportunity to continuously strengthen communication and cooperation with customers, continuously improve product and service levels, actively expand overseas business, and strive to be a leading international pharmaceutical company.
27
2023-10
Scan QR code for mobile view
TEL.
ADD.
Manufacturing Site Address:
No. 22, Jiankang Road,
Economic Development Zone,
Yuechi County 638300,
Sichuan Province,
China.